- Home
- IMMR vs AARD Comparison
IMMR vs AARD Comparison
Compare IMMR & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMR
- AARD
- Stock Information
- Founded
- IMMR 1993
- AARD 2017
- Country
- IMMR United States
- AARD United States
- Employees
- IMMR N/A
- AARD N/A
- Industry
- IMMR Computer peripheral equipment
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- IMMR Technology
- AARD Health Care
- Exchange
- IMMR Nasdaq
- AARD Nasdaq
- Market Cap
- IMMR 237.6M
- AARD 216.6M
- IPO Year
- IMMR 1999
- AARD 2025
- Fundamental
- Price
- IMMR $7.94
- AARD $8.69
- Analyst Decision
- IMMR Strong Buy
- AARD Strong Buy
- Analyst Count
- IMMR 2
- AARD 4
- Target Price
- IMMR $12.25
- AARD $30.50
- AVG Volume (30 Days)
- IMMR 500.5K
- AARD 113.9K
- Earning Date
- IMMR 03-12-2025
- AARD 01-01-0001
- Dividend Yield
- IMMR 4.73%
- AARD N/A
- EPS Growth
- IMMR 57.07
- AARD N/A
- EPS
- IMMR 2.04
- AARD N/A
- Revenue
- IMMR $163,133,000.00
- AARD N/A
- Revenue This Year
- IMMR $988.71
- AARD N/A
- Revenue Next Year
- IMMR $288.32
- AARD N/A
- P/E Ratio
- IMMR $3.93
- AARD N/A
- Revenue Growth
- IMMR 338.21
- AARD N/A
- 52 Week Low
- IMMR $7.06
- AARD $8.60
- 52 Week High
- IMMR $13.94
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- IMMR 48.99
- AARD N/A
- Support Level
- IMMR $7.35
- AARD N/A
- Resistance Level
- IMMR $7.65
- AARD N/A
- Average True Range (ATR)
- IMMR 0.26
- AARD 0.00
- MACD
- IMMR 0.04
- AARD 0.00
- Stochastic Oscillator
- IMMR 82.00
- AARD 0.00
About IMMR Immersion Corporation
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.